[O-31] Oral Session 31

[O-31-4] Eculizumab post-marketing surveillance for neuromyelitis optica spectrum disorder-2nd interim report

^○Kazumi Okamura¹, Ichiro Nakashima², Hidekazu Kikui³, Kazuo Fujihara^4,5 (1.Medical Affairs, Alexion Pharma GK, Japan, 2.Department of Neurology, Tohoku Medical and Pharmaceutical University, 3.Drug Safety, Alexion Pharma GK, 4.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, 5.Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience (STRINS))